Promising drug cocktail aims to shrink esophageal tumors before surgery
NCT ID NCT07388095
First seen Feb 04, 2026 · Last updated May 25, 2026 · Updated 12 times
Summary
This study is testing whether giving a combination of three drugs (adebrelimab, nimotuzumab, and chemotherapy) before surgery can help people with a certain type of esophageal cancer. The goal is to shrink or eliminate the tumor before the operation, potentially improving long-term outcomes. The trial will enroll 22 adults with resectable esophageal squamous cell carcinoma who have not had prior treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.